Atyr Pharma Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Atyr Pharma Inc 's ROA in the second quarter of 2026?
Atyr Pharma Inc recorded a cumulative net loss of $-61 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -69.67%.

However, within the Healthcare sector 738 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the first quarter of 2026 from 4236 to 4837.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	-31.23 %	-18.09 %	0.21 %	23.53 %	1.05 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-61	-70	-74	-75	-67
Return On Assets (TTM)	-69.67 %	-73.56 %	-74.41 %	-75.46 %	-70.54 %
ATYR's Total Ranking	# 4837	# 4236	# 4263	# 4310	# 4954
Total Assets (TTM) in million	70	80	93	107	102
Seq. Total Assets Change	-12.34 %	-14.35 %	-12.8 %	5.04 %	4.41 %
Seq. Net Income Change	-	-	-	-	-

ATYR's 5 Years Annual ROA >> Back to ATYR Management Effectiveness >> Compare ATYR ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 112
Sector	# 739
Overall	# 4756

Return On Assets Statistics
High	Average	Low
219.18 %	-44.97 %	-74.7 %
(Dec 31 2015)		(Sep 30 2025)

Financial Statements
Atyr Pharma Inc 's Assets	$ 70 million	ATYR's Balance sheet
Atyr Pharma Inc 's Income	$ -10 million	Quarterly ATYR's Income Statement
ATYR's Income by Division		See ATYR's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	0.21 %	-19.67 %	29.9 %	-22.74 %	207.54 %
Total Assets in million	93	93	116	89	115
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-74	-64	-50	-45	-34
Annual Return On Assets	-79.7 %	-68.99 %	-43.63 %	-50.99 %	-29.34 %

ATYR's 5 Years Annual ROA >> Back to ATYR Management Effectiveness >> Compare ATYR ROA to its Competitors

More Return On Assets Ratios
ATYR's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ATYR's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ATYR's Competitors
Subscribers only: Roa for Atyr Pharma Inc 's Suppliers
Subscribers only: Return On Assets for ATYR's Customers

You may also want to know
ATYR's Roi	ATYR's Inventory Turnover Ratio	ATYR's Growth Rates	ATYR's Dividend Comparisons
	ATYR's Profitability Ratios	ATYR's Asset Turnover Ratio	ATYR's Dividend Growth
ATYR's Roe	ATYR's Valuation Ratios	ATYR's Financial Strength Ratios	ATYR's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-08-14T08:40:22+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.